Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
GemVax & Kael
GV1001 0.56 mg, 1.12 mg or placebo is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times. 1. Control group (placebo): 30 subjects 2. Study group 1 (GV1001 0.56 mg): 30 subjects 3. Study group 2 (GV1001 1.12 mg): 30 subjects.
Age
55–85
Sex
ALL
Healthy volunteers
Not accepted